Samrat Pharmachem Ltd

AI
Samrat Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Samrat Pharmachem Ltd

₹ 278 -3.68%
23 Oct - close price
samratpharmachem.com BSE: 530125
About

Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]

Key Points

Business Overview:[1]
Samrat Pharmachem Ltd began operations focused on iodine chemistry, expanded its iodine derivatives portfolio, and entered applications across pharmaceuticals, salt, animal feed, textiles, and tyre cord manufacturing.
The company operates an R&D-focused manufacturing facility in Ankleshwar and exports pharmaceutical ingredients globally, serving multinational customers with facilities approved by regulatory agencies including USFDA, EU GMP, UK MHRA, Health Canada and WHO.

Website BSE
  • Market Cap ₹ 85.7 Cr.
  • Current Price ₹ 278
  • High / Low ₹ 310 / 190
  • Stock P/E
  • Book Value ₹ 221
  • Dividend Yield 0.00 %
  • ROCE -2.88 %
  • ROE -5.19 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Company has a low return on equity of 2.15% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
57.48 79.74 61.67 82.68 80.82 70.17 63.66 71.20 75.65 78.87 63.43 71.77 79.76
56.71 79.51 61.56 81.32 78.24 66.80 59.48 71.07 75.52 79.23 64.08 73.01 78.87
Operating Profit 0.77 0.23 0.11 1.36 2.58 3.37 4.18 0.13 0.13 -0.36 -0.65 -1.24 0.89
OPM % 1.34% 0.29% 0.18% 1.64% 3.19% 4.80% 6.57% 0.18% 0.17% -0.46% -1.02% -1.73% 1.12%
0.36 0.30 0.42 0.30 0.59 0.49 0.00 -0.11 0.69 0.05 0.40 -0.31 0.99
Interest 0.22 0.13 0.23 0.11 0.19 0.17 0.10 0.22 0.44 0.26 0.13 0.14 0.11
Depreciation 0.16 0.16 0.16 0.16 0.16 0.17 0.17 0.16 0.17 0.18 0.19 0.19 0.19
Profit before tax 0.75 0.24 0.14 1.39 2.82 3.52 3.91 -0.36 0.21 -0.75 -0.57 -1.88 1.58
Tax % 18.67% 175.00% -142.86% 0.00% 26.60% 24.43% 28.90% 11.11% 209.52% -21.33% -19.30% 8.51% 44.94%
0.61 -0.19 0.34 1.40 2.07 2.66 2.78 -0.40 -0.23 -0.59 -0.46 -2.04 0.88
EPS in Rs 1.97 -0.61 1.10 4.53 6.70 8.61 9.00 -1.29 -0.74 -1.91 -1.49 -6.60 2.85
Raw PDF
Upcoming result date: 14 November 2026

Profit & Loss

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
47 63 73 93 111 137 179 222 311 282 286 290 294
46 62 69 87 108 131 170 197 287 279 276 292 295
Operating Profit 1 1 4 6 3 7 9 24 24 2 10 -2 -1
OPM % 2.5% 1.9% 5% 6% 2.9% 4.8% 4.8% 11% 8% 0.9% 3.6% -0.7% -0.5%
0 0 0 0 0 1 0 1 0 1 1 1 1
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 0 0 0 0 0 0 0 1 1 1 1 1 1
Profit before tax 0 0 3 5 2 6 7 24 23 3 10 -3 -2
Tax % 35% 33% 37% 35% 29% 27% 27% 27% 26% 14% 28% 11%
0 0 2 3 2 4 5 17 17 2 7 -3 -2
EPS in Rs 1.04 0.97 5.66 10.42 4.98 13.72 17.25 55.60 53.82 6.99 23.01 -10.71 -7.15
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 2% 2% 14% 4% 0%
Compounded Sales Growth
10 Years: 16%
5 Years: 10%
3 Years: -2%
TTM: 5%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -146%
Stock Price CAGR
10 Years: 20%
5 Years: 6%
3 Years: -10%
1 Year: -6%
Return on Equity
10 Years: 14%
5 Years: 13%
3 Years: 2%
Last Year: -5%

Balance Sheet

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 10 11 12 15 17 21 27 44 60 62 69 65
3 6 7 9 7 9 9 8 19 8 10 11
10 17 14 13 14 25 19 30 35 48 40 46
Total Liabilities 26 36 36 41 40 58 57 85 117 122 122 124
7 7 7 7 7 7 9 10 11 11 10 12
CWIP 0 0 0 0 0 1 0 0 0 0 0 1
Investments 0 2 0 0 0 0 0 0 2 3 4 4
19 27 29 34 33 50 48 75 104 108 107 108
Total Assets 26 36 36 41 40 58 57 85 117 122 122 124

Cash Flows

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-1 -0 -3 0 2 -1 5 17 -9 9 -10 9
0 -2 1 -2 2 -2 -3 -1 -3 -0 0 -3
0 2 1 2 -4 2 -2 -2 10 -11 0 -0
Net Cash Flow -0 -0 -1 -1 1 -1 -0 14 -3 -2 -10 6
Free Cash Flow -1 -1 -4 -0 2 -3 3 16 -11 9 -11 6
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -29% -25% -73% 17% 126% -7% 81% 78% 0% 503% -84% -493%

Ratios

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 74 93 59 86 69 74 67 72 61 90 72 64
Inventory Days 38 37 41 31 28 55 25 24 43 28 52 56
Days Payable 76 104 43 46 45 67 39 45 42 65 53 55
Cash Conversion Cycle 36 26 58 70 52 61 53 51 62 53 71 65
Working Capital Days 19 14 34 32 37 39 36 32 40 47 68 52
ROCE % 7% 5% 16% 23% 12% 22% 24% 52% 35% 3% 13% -3%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Revenue Share of Total Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Employees on Payroll
count
Iodine Crude Consumption (Major Raw Material)
MT

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
48.64% 48.64% 48.64% 48.95% 49.09% 49.09% 49.09% 49.09% 49.09% 49.09% 49.09% 49.09%
3.24% 3.24% 3.24% 3.24% 3.24% 3.24% 0.00% 3.24% 3.24% 3.24% 3.24% 3.24%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.24% 0.00% 0.00% 0.00% 0.00% 0.00%
48.13% 48.13% 48.13% 47.81% 47.66% 47.67% 47.67% 47.67% 47.67% 47.67% 47.66% 47.67%
No. of Shareholders 8,0657,4787,1696,9846,8446,7856,7526,6996,4886,3116,3306,133

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings